HomeNewsTrendsHealthThailand to combine Sinovac, AstraZeneca vaccine doses to boost protection: Minister

Thailand to combine Sinovac, AstraZeneca vaccine doses to boost protection: Minister

The move is the first publicly announced mix-and-match of a Chinese vaccine and a Western-developed shot, as a new preliminary Thai study raised doubts about the longer-term protection of the two-dose course Sinovac vaccine.

July 12, 2021 / 14:15 IST
Representative image (Image: AP)

Thailand will use AstraZeneca Plc's COVID-19 vaccine as a second dose for those who received Sinovac's shot as their first dose in a bid to increase protection, it said on Monday.

The move is the first publicly announced mix-and-match of a Chinese vaccine and a Western-developed shot, as a new preliminary Thai study raised doubts about the longer-term protection of the two-dose course Sinovac vaccine.

"This is to improve protection against the Delta variant and build a high level of immunity against the disease," Health Minister Anutin Charnvirakul told reporters, adding that the second dose of AstraZeneca would come three or four weeks after the first Sinovac shot.

There have been no studies specifically on mixing Sinovac and AstraZeneca released, but a growing number of countries are looking at mix-and-match of different vaccines or giving a third booster dose amid concerns new and more contagious variants may escape approved vaccines.

The announcement came a day after Thailand's health ministry said 618 medical workers out of 677,348 personnel who received two doses of the Sinovac vaccine became infected from April to July. One nurse died.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Neighbouring Indonesia has also reported breakthrough infections among medical and frontline workers who are fully inoculated with the Sinovac vaccine.

Thailand now plans to give booster shots of imported mRNA vaccine to its frontline workers - who were given imported Sinovac before the locally manufactured AstraZeneca vaccine was available in June. Indonesia is considering similar boosters.

On Monday, a preliminary Thai study of 700 medical workers indicated that Sinovac's protection rate as measured by antibody level ranged between 60 percent and 70 percent for the first 60 days after the second dose, but the rate steadily went down over time and appeared to halve every 40 days.

"From our research, if our medical staff received two doses of Sinovac  ... they should definitely get a third booster shot," Sira Nanthapisal, a researcher at Thammasat University's Faculty of Medicine, told Reuters.

The researchers have yet to release their full study data.

"They can do that either between AstraZeneca or Pfizer when it arrives, and we will continue to monitor their antibodies," Sira said.

An AstraZeneca representative declined to comment on Thailand's decision, saying only that vaccination policy is a matter for each country to decide.

Sinovac did not respond to requests for comment on Monday.

Last month, Sinovac spokesman Liu Peicheng told Reuters  preliminary results from blood samples of the vaccinated showed a three-fold reduction in neutralizing effect against the Delta variant and suggested a third Sinovac shot could elicit more durable antibody reaction.

Thailand on Monday implemented its toughest coronavirus restrictions in more than a year in Bangkok and surrounding provinces, amid a fast-rising wave of the highly transmissible Alpha and Delta variants, with cases rising to nearly 10,000 per day and record deaths.

The measures, initially for two weeks, include widespread suspensions by airlines and bus firms, a curfew, mall closures and a five-person limit on gatherings.

The vast majority among the total 345,027 cases and 2,791 fatalities have been since April after nearly a year of largely controlling the virus, but there has been a slow start to its mass vaccination rollout that only began last month.

Follow our full coverage of the coronavirus pandemic here.

Reuters
first published: Jul 12, 2021 01:55 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347